Inflammatory bowel diseases (IBDs) are a group of inflammatory conditions characterized by chronic, uncontrolled inflammation of the gastrointestinal tract. Reported prevalence is high in the United States and northern Europe, while the incidence varies greatly across the rest of Europe. Glucocorticosteroids are the standard treatment for IBD, but due to adverse events their use can be limited. However, new formulations of glucocorticosteroids have been developed to reduce systemic activation. The aim of this review was to assess and summarize the efficacy and safety of new formulations of glucocorticosteroids. A MEDLINE search identified publications focused on new formulations of nonsystemic steroidbased drugs for IBD and benefits and limitations of each of the new glucocorticosteroid formulations were identified. Budesonide has good efficacy and is an established treatment for Crohn's disease; it has been shown to be beneficial for the induction of remission in these patients, although it is not recommended for the maintenance of induced remission. Glucocorticosteroids are not recommended for the maintenance of remission in patients with IBD. However, a recent study suggested that beclomethasone dipropionate may be effective for prolonged treatment in patients in the postacute phase of Crohn's disease who were treated with a short course of systemic steroids. The efficacy of fluticasone propionate and prednisolone metasulphobenzoate in IBD is not well established given the small number of patients enrolled in the few published clinical trials. While the tolerability of these glucocorticosteroids is favourable, more research comparing these new agents with traditional systemic glucocorticosteroids is warranted.
Introduction
Inflammatory bowel diseases (IBDs) are inflammatory conditions characterized by chronic, uncontrolled inflammation of the gastrointestinal tract [Papadakis and Targan, 2000 ]. Crohn's disease and ulcerative colitis are the two primary types of IBD [Hanauer, 2006] , while unclassified colitis (IBDU) is a form of colitis with clinical and pathological characteristics that do not meet the criteria for classification as either ulcerative colitis or Crohn's disease [Burakoff, 2004] . The term indeterminate colitis is used for IBDU when classification is impossible even after examination of a surgical specimen. Other rarer cases include collagenous colitis [Fernandez-Banares et al. 2003 ], lymphocytic colitis [Fernandez-Banares et al. 2003 ], ischaemic colitis [Green and Tendler, 2005] , diversion colitis [Geraghty and Talbot, 1991] , colitis associated with diverticular disease and Behçet's colitis [Akpek and Weinberg, 2003] .
Many regions, such as North America [Hanauer, 2006] and the UK [Montgomery et al. 1998 ], have reported a high prevalence of IBD -approximately 100 people per 100,000 people in the USA are diagnosed with the disease [Crohn's and Colitis Foundation of America, 2012] . The incidence of IBD varies greatly across Europe, with a much higher incidence reported in northern compared with southern countries [Shivananda et al. 1996 ].
Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity
IBD can be difficult to manage clinically. Currently, treatment can result in recovery and sometimes mucosal healing, but there is no cure. Disease flares can range from mild to severe and involve symptoms such as diarrhoea, abdominal pain, fever and rectal bleeding [Carter et al. 2004; Bernstein et al. 2010] . Current treatment guidelines recommend a variety of therapeutic options depending on disease activity, which tract of the intestine is involved, complications and symptoms of the disease [Carter et al. 2004; Travis et al. 2006; Bernstein et al. 2010] . Such treatments include glucocorticosteroids, aminosalicylates (such as sulfasalazine or mesalamine (5-aminosalicylic acid)], immunosuppressors (such as thiopurines or methotrexate) and biological therapies [such as tumour necrosis factor α (TNFα) inhibitors] [Carter et al. 2004 , Bernstein et al. 2010 . In patients with ulcerative colitis with a flare that does not respond to intensive medical therapy, including intravenous steroids, cyclosporine and anti-TNF, surgery is recommended; however, surgery is only recommended for complications of Crohn's disease and, reluctantly, for treatment failure [Carter et al. 2004 ].
Overview of glucocorticosteroids in inflammatory bowel disease: use and limitations
Glucocorticosteroids are the standard treatment for IBD as they result in rapid remission of disease activity [Carter et al. 2004 , Travis et al. 2006 ]. Longstanding treatment with glucocorticosteroids is limited because of adverse events associated with their use (such as hypothalamic pituitary adrenal axis suppression) [Stein and Hanauer, 2000] and the possible development of steroiddependent disease [Aceituno et al. 2007 ]. As a result, maintenance treatment with systemic glucocorticosteroids is not advised. New formulations of glucocorticosteroids have been developed with the aim of limiting systemic activity and reducing glucocorticosteroid adverse events. The pharmacokinetic profiles of the second-generation topical oral or rectal preparations are such that the agents have high local efficacy in the gut, but minimal systemic bioavailability due to highly efficient first-pass hepatic inactivation, thus minimizing any adverse systemic effects [Campieri, 2002; Mulder and Tytgat, 1993; Girlich and Scholmerich, 2012] .
Glucocorticosteroids for which new formulations have been developed include budesonide, beclomethasone dipropionate (BDP), fluticasone propionate and prednisolone metasulphobenzoate.
Recent reviews have highlighted the safety and efficacy of second-generation glucocorticosteroids, particularly budesonide and BDP, in the treatment of Crohn's disease and ulcerative colitis [De Cassan et al. 2012; Nunes et al. 2012 ]. This review was undertaken to extend the discussion and report the safety and efficacy of these and other second-generation glucocorticosteroids (fluticasone and prednisolone metasulphobenzoate) in the treatment of IBD, including pouchitis and lymphocytic colitis.
Search methods
To identify publications reporting the efficacy and tolerability of new formulations of nonsystemic steroid-based drugs for the treatment of IBD, a literature search was conducted on the online database Medline using the Ovid interface. The search was conducted on 11 May 2011 using the terms 'inflammatory bowel disease', 'Crohn's disease', 'ulcerative colitis', 'indeterminate colitis', 'unclassified colitis', 'beclomethasone', 'fluticasone', 'prednisolone' and 'budesonide'. Only studies conducted in humans and published in English were included; data were not limited by date. Papers were manually searched and relevant articles were selected. Papers that discussed glucocorticosteroid drugs which had inherent limited systemic activity or discussed formulations designed to reduce systemic activity were included. Additional articles were identified from the reference lists of reviews and from the author's own experience in the field.
Advances in therapeutic approaches to glucocorticosteroid therapy

Budesonide
Budesonide is a glucocorticosteroid which was originally designed as an inhaled formulation for the treatment of asthma and noninfectious rhinitis. Budesonide is regularly used for the treatment of Crohn's disease and, to a lesser extent, for the treatment of ulcerative colitis. There are two formulations of oral budesonide regularly employed in Crohn's disease: Entocort (AstraZeneca, London, UK), a controlled-ileal release formulation using a gelatine capsule containing acidstable microgranules (http://www1.astrazeneca-us. com/pi/entocortec.pdf), and Budenofalk (Dr Falk Pharma GmbH, Freiburg im Breisgau, Germany), a pH-dependent release tablet which dissolves at pH less than 6.0 (http://www.medicines.org.uk/ emc/medicine/16908/SPC/Budenofalk+3mg+ gastro-resistant+capsules/). Also, a once-daily oral controlled-release formulation of budesonide that extends release throughout the colon using multimatrix (MMX) technology (budesonide MMX) has completed phase III development with Cosmo Pharmaceuticals (Lainate, Italy) and is currently in the regulatory preregistration phase for the treatment of ulcerative colitis in the USA and Europe (http://www.cosmopharmaceuticals.com/activities/pipeline/budesonide.aspx).
Other budesonide formulations have been investigated and are now used for the treatment of IBD outside the USA. These include a topical budesonide enema Lemann et al. 1995] and budesonide foam enema [Brunner et al. 2005] .
Efficacy in Crohn's disease
Many trials have been conducted to establish the efficacy of oral budesonide as induction therapy in patients with Crohn's disease. Two randomized, double-blind, placebo-controlled studies investigated the treatment of flare in patients with mild-to-moderate active Crohn's disease of the ileum or ascending colon, and showed that controlled-ileal-release budesonide capsules were more effective than placebo for induction of remission (Table 1) [Greenberg et al. 1994; Tremaine et al. 2002] . A controlled-ileal-release formulation of budesonide more effectively induced remission than a slow-release formulation of mesalamine in patients with active Crohn's disease [Thomsen et al. 1998 ]. Also, an oral pH-modified budesonide was as effective as mesalamine in patients with mildly to moderately active Crohn's disease (Table 1) [Tromm et al. 2011] . However, these results should be interpreted cautiously because of mesalamine's limited efficacy in Crohn's disease [Travis et al. 2006 ].
Compared with other glucocorticosteroids, budesonide administered as an oral, controlledileal-release capsule [Rutgeerts et al. 1994; Campieri et al. 1997] or as a pH-modified release tablet [Bar-Meir et al. 1998 ] has been shown to be as effective as prednisone for the treatment of active Crohn's disease involving the terminal ileum or the right colon (Table 1) . Furthermore, oral controlled-ileal-release budesonide capsules were associated with similar toxicity to placebo, with no increase in glucocorticosteroid adverse events in treatment-refractory patients with steroid-dependent Crohn's disease undergoing prednisolone tapering (Table 1) .
There is debate about whether budesonide is effective for the maintenance of clinical remission in patients with Crohn's disease. Two randomized, double-blind studies suggested that controlledileal-release budesonide significantly prolongs remission in patients with ileal or ileo-caecal Crohn's disease [Greenberg et al. 1996; ], although relapse rates in the budesonide and placebo groups were similar (Table 1) . Another study of comparable design suggested otherwise, showing no difference between budesonide and placebo in terms of relapse rate and time to relapse [Ferguson et al. 1998 ]. A further trial investigating oral pH-modified-release budesonide also found that budesonide was not effective for maintaining steroid-induced remission compared with placebo (Table 1) [Gross et al. 1998 ]. Finally, a trial investigating modifiedrelease budesonide showed that budesonide and placebo had similar relapse rates after 1 year of treatment (Table 1) [Hanauer et al. 2005] .
A Cochrane review evaluating the efficacy and safety of short-term oral budesonide for the induction of remission in Crohn's disease [Seow et al. 2008 ] demonstrated that it was more effective than placebo or mesalamine, and less effective but better tolerated than conventional systemic steroids. Another Cochrane review investigating the efficacy of oral budesonide for the maintenance of remission in Crohn's disease was published in 2009, and concluded that budesonide is not recommended for the prevention of clinical relapse [Benchimol et al. 2009 ].
Efficacy in ulcerative colitis
Only a few double-blind, randomized controlled trials have investigated the efficacy of budesonide in patients with ulcerative colitis. These showed that a budesonide enema was effective and safe for the treatment of active distal ulcerative colitis and ulcerative proctitis compared with placebo [Hanauer et al. 1998 ]; however, it was not shown to be effective in maintaining remission in these patients (Table 2) [Lindgren et al. 2002] . Furthermore, an oral extended-release formulation of budesonide (budesonide MMX) appeared to be effective in patients with active left-sided ulcerative colitis; it induced significant clinical improvement in these patients compared with placebo (Table 2 ) [D'Haens et al. 2010] . Only one trial compared budesonide with another corticosteroid. This trial showed that oral sustainedrelease budesonide was as effective and well tolerated as prednisolone in patients with active distal ulcerative colitis (Table 2 ) .
A Cochrane review investigating the efficacy of oral budesonide for the induction of remission in ulcerative colitis was published in 2010 and concluded that there was no evidence to suggest that oral budesonide is effective for the induction of remission in ulcerative colitis [Sherlock et al. 2010] . Conversely, data from two randomized, double-blind trials reported in 2011 and 2012 showed that oral budesonide MMX 9 mg, but not 6 mg, once daily was significantly more effective than placebo for the induction of remission (Table 2 ) [Sandborn et al. 2012; Travis et al. 2011 ]. However, two slow-release delivery systems were developed for budesonide which are presently on the market. Both agents use enteric-coated (Eudragit, Evonik Industries, Essen, Germany) pellets with a rate-limiting polymer containing the active drug. These time-dependent and pH-dependent delivery systems (controlled ileal release, Entocort CIR, AstraZeneca; and Budenofalk, Dr Falk Pharma GmbH) release the drug in the distal ileum and the cecum, where approximately 70% of the total absorption takes place, making it effective for treatment of active distal ileal and right-sided colonic Crohn's disease.
A new controlled release system, MMX extendedrelease tablets, characterized by a multimatrix structure, has recently been developed for 5-aminosalicylic acid preparations and marketed under the trade name of Lialda (Cosmo Pharmaceuticals, Lainate, Italy) or Mezavant (Shire, Dublin, Ireland). Data from two randomized, double-blind trials reported in 2011 and 2012 showed that oral budesonide MMX 9 mg, but not 6 mg, once daily was significantly more effective than placebo for the induction of remission (Table 2 ) [Sandborn et al. 2011; Travis et al. 2011 ].
The most recent study, an 8-week, randomized, double-blind trial to evaluate the efficacy of budesonide MMX for induction of remission in 509 patients with active, mild-to-moderate UCshowed that not only was remission induction greater with the 9mg dose, but so was endoscopic improvement. Moreover, both doses of budesonide MMX and mesalamine resulted in greater clinical improvement and symptom resolution compared with placebo, and tolerability was similar in all groups. [Sandborn et al. 2012] Further trials investigating budesonide in patients with ulcerative colitis are consequently required.
Efficacy in pouchitis
Two trials have investigated the efficacy of budesonide in patients with pouchitis (Table 3) ; one was an open-label observational study investigating the efficacy and tolerability of oral, controlledileal-release budesonide and one was a randomized, double-blind study comparing a budesonide enema with metronidazole [Sambuelli et al. 2002] . These trials showed that oral budesonide is effective in inducing remission in patients with active refractory pouchitis , and that the budesonide enema was as effective as oral metronidazole in patients with pouchitis, but with improved tolerability [Sambuelli et al. 2002] . These results indicated that budesonide may be a valuable treatment option for patients with pouchitis; however, both studies suggested that more randomized controlled trials are warranted.
Efficacy in lymphocytic colitis
Only one clinical trial has investigated the efficacy of budesonide in patients with lymphocytic colitis (Table 3 ). In a 6-week, randomized, double-blind placebo-controlled study [Miehlke et al. 2009 ] in 42 patients with lymphocytic colitis and chronic diarrhoea, 86% of patients achieved clinical remission with budesonide 9 mg/day versus 48% with placebo (p = 0.01).
Evidence from a retrospective study of patients with lymphocytic colitis [Simondi et al. 2010] showed that approximately 80% of patients improved on treatment with oral topical steroids (including budesonide) which is a similar rate to that achieved with mesalamine.
Tolerability
The tolerability of budesonide is well established: compared with conventional glucocorticosteroids it is associated with less glucocorticosteroidrelated adverse events. A pooled safety analysis investigating the long-term effects of oral, controlled-release budesonide capsules showed that budesonide was generally well tolerated in patients with Crohn's disease. The most common adverse events associated with budesonide capsules are gastrointestinal and endocrine system related events, with only rare occurrences of the clinically severe adverse events associated with traditional systemic glucocorticosteroids [Lichtenstein et al. 2009 ].
The most debilitating adverse events associated with glucocorticosteroids are osteopenia and bone fractures [D'Haens et al. 1998 ]. A few trials have been conducted to investigate the bonerelated adverse events associated with budesonide; however, the results of these are conflicting. Short-term therapy with controlled-ileal-release budesonide did not impair osteoblast activity compared with oral methylprednisolone [D'Haens et al. 1998 ], and was associated with better preserved bone mass compared with prednisolone in corticosteroid-naïve patients [Schoon et al. 2005 ]. However, it has been shown that maintenance treatment with oral budesonide may be associated with lumbar spine and femoral neck bone loss [Cino and Greenberg, 2002] .
Beclomethasone dipropionate
BDP is a second-generation glucocorticosteroid with topical effects and minimal systemic activity.
There are many formulations of BDP available for the treatment of IBD, including a topical formulation and an oral, enteric-coated, controlledrelease tablet (Clipper, Chiesi Ltd, Cheadle, UK; http://www.medicines.org.uk/emc/medicine/ 21329/SPC/Clipper+5mg+sustained+release+tabl ets/). This controlled-release tablet permits local delivery of BDP at the site of the inflammatory process in the mucosa of the distal ileum and proximal colon. These tablets have been launched in Belgium, Italy, Spain and the UK as a oncedaily treatment, in combination with mesalamine, for mild-to-moderate, active ulcerative colitis.
Controlled-release tablets are also being investigated for the treatment of Crohn's disease [Tursi et al. 2006 , Prantera et al. 2011 .
Efficacy in Crohn's disease
No double-blind, randomized trials have investigated the induction of remission with BDP in Crohn's disease. However, results from a randomized, open-label trial indicated that BDP seems to be less effective than budesonide for the treatment of flares in patients with mild-to-moderate active Crohn's disease [Tursi et al. 2006 ]. A recently published trial of 6 months' maintenance therapy showed that oral, controlled-release BDP was well tolerated and significantly reduced the relapse rate in patients with postactive Crohn's ileitis compared with placebo, after induction of remission with a short course of systemic glucocorticosteroids (Table 1) [Prantera et al. 2011 ]. Longterm steroid use is currently not recommended in patients with Crohn's disease and further studies to establish the efficacy of BDP as a maintenance therapy in patients with Crohn's disease are recommended.
Efficacy in ulcerative colitis
The efficacy of BDP in patients with ulcerative colitis has been well established; eight doubleblind randomized trials have been published. These trials showed that topical administration of a BDP enema was as effective as first-generation beclomethasone phosphate and was preferable in terms of tolerability, as it did not affect adrenocortical function in patients with distal ulcerative colitis (Table 2 ) [Bansky et al. 1987; Halpern et al. 1991] . Furthermore, topical BDP enema was as effective as mesalamine foam in patients with mild-to-moderate distal ulcerative colitis (Table 2 ) [Biancone et al. 2007 ].
While BDP is effective in ulcerative colitis, the degree of efficacy compared with other glucocorticosteroids is not well defined. There is conflicting evidence regarding the efficacy of a BDP enema compared with a prednisolone sodium enema. Two studies, one in patients with distal ulcerative colitis and one in patients with more extensive ulcerative colitis, suggested that topical administration of BDP is as effective as a prednisolone sodium enema and does not affect the hypothalamic-pituitary-adrenal axis function [Mulder et al. 1989; Campieri et al. 1998 ]. On the contrary, another trial in patients with ulcerative proctitis suggested that a BDP enema was less effective than prednisolone 21-phosphate enema in ulcerative proctitis ( et al. 1988] . Finally, three studies compared the efficacy of BDP, mesalamine and a combination of both drugs: one investigated topical mesalamine and a BDP enema [Mulder et al. 1996] , one investigated oral, controlled-release BDP with mesalamine [Rizzello et al. 2002] , and another compared topical BDP (36.7%) and topical mesalamine (29.2%) in 217 patients with distal active ulcerative colitis and demonstrated similar clinical remission rates between the two treatments [Gionchetti et al. 2005 ].
These trials showed that BDP alone was more effective than mesalamine alone in patients with extensive or left-sided ulcerative colitis, and that the combination of BDP and mesalamine was more effective than either BDP or mesalamine alone (Table 2) .
Efficacy in pouchitis and lymphocytic colitis
There are no published randomized clinical trials of BDP in pouchitis or lymphocytic colitis. One retrospective study in patients with lymphocytic colitis found that 39% of patients were treated with oral topical steroids (including beclomethasone) and the clinical response rates achieved (approximately 80%) were similar to those achieved with mesalamine [Simondi et al. 2010] .
Tolerability
The tolerability of BDP is well documented (Tables  1 and 2) . As a second-generation glucocorticosteroid with much lower systemic absorption, it is associated with significantly fewer glucocorticosteroid adverse events than first-generation betamethasone phosphate, particularly with respect to hypothalamicpituitary-adrenal axis suppression [Bansky et al. 1987; Halpern et al. 1991] . The most commonly reported adverse events associated with 6 months' administration of BDP, however, were gastrointestinal related, including moon face, hyperthyroidism and Cushing's syndrome [Prantera et al. 2011 ].
Other glucocorticosteroids
Fluticasone
Fluticasone propionate is an oral glucocorticosteroid that is used in the management of IBD.
Currently, no randomized, controlled trials have been conducted to investigate the efficacy of fluticasone propionate in patients with Crohn's disease. However, an observational study which investigated the efficacy of oral fluticasone propionate in 12 patients with Crohn's disease suggested that it may be an effective treatment for this disease. After 3 weeks of treatment, fluticasone propionate significantly reduced Crohn's Disease Activity Index scores without inducing typical systemic corticosteroid side effects [De Kaski et al. 1991] .
Two double-blind, randomized controlled trials have explored the efficacy and tolerability of oral fluticasone propionate in patients with ulcerative colitis (Table 2) . Their negative results do not support the use of fluticasone propionate in this patient population. In the first placebo-controlled trial, fluticasone propionate was not found to be effective for the treatment of distal ulcerative colitis in 60 patients with active disease [Angus et al. 1992] . After 4 weeks of treatment, there was no difference between the clinical response observed in patients receiving fluticasone propionate or placebo. Furthermore, in the second study, fluticasone propionate appeared less effective than tapering of prednisolone in a study of 250 patients with active ulcerative colitis [Hawthorne et al. 1993] . After 2 weeks, the treatment response was significantly greater with prednisolone than fluticasone propionate; this difference was no longer significant by the end of the 4-week treatment period, possibly due to rapid tapering of the prednisolone dose, but there remained a trend towards significance (Table 2) . However, fluticasone propionate was associated with very few of the adverse events typical of glucocorticosteroids in this study, with minimal suppression of the hypothalamic-pituitary-adrenal axis. This suggested that fluticasone propionate may be of use for short-term treatment in this patient population (Table 2) .
There are no published randomized clinical trials of fluticasone in pouchitis or lymphocytic colitis.
Prednisolone metasulphobenzoate
Prednisolone metasulphobenzoate is a formulation of prednisolone which is not absorbed as extensively as previous formulations, such as prednisolone-21-phosphate. Prednisolone metasulphobenzoate is used for the treatment of ulcerative colitis and can be administered as an oral controlledrelease formulation (Predocol, Enterotech Limited, Jersey, UK) [Rhodes et al. 2008] . Additionally, rectal administration of a foam formulation of prednisolone metasulphobenzoate (PredFoam, Forest Laboratories UK Limited, Bexley, UK) has been approved for the treatment of ulcerative colitis and proctitis (http://www.drugs.com/uk/ predfoam-spc-1068.html).
Only a few double-blind, randomized controlled trials have been published reporting the efficacy and tolerability of prednisolone metasulphobenzoate in patients with ulcerative colitis. First, Predocol was shown to have similar efficacy to a conventional tapering prednisolone regimen in patients with active ulcerative colitis (Table 2 ) [Rhodes et al. 2008] . Prednisolone metasulphobenzoate was also shown to be associated with significantly fewer glucocorticosteroid-associated adverse events than the tapered prednisolone regimen (Table 2) . In another two studies, a prednisolone metasulphobenzoate enema was shown to be as effective as a prednisolone-21-phosphate enema [McIntyre et al. 1985] , and more effective than a sucralfate enema [Riley et al. 1989] in patients with active distal ulcerative colitis and mild-to-moderate ulcerative colitis respectively (Table 2) . Furthermore, while the prednisolone metasulphobenzoate enema was shown to be as effective as the prednisolone-21-phosphate enema, peak plasma concentrations and the area under the concentration-time curve of prednisolone were lower after rectal administration of prednisolone metasulphobenzoate compared with prednisolone-21-phosphate. This suggested that the metasulphobenzoate formulation of prednisolone may reduce the systemic adverse effects of prednisolone to a greater extent than the phosphate formulation, which is particularly an advantage when long-term prednisolone treatment is required [McIntyre et al. 1985] .
There are no published randomized clinical trials of prednisolone metasulphobenzoate in pouchitis or lymphocytic colitis.
The tolerability of prednisolone metasulphobenzoate has been well established in trials to date. These showed that oral prednisolone metasulphobenzoate is associated with fewer corticosteroid-related adverse events than oral prednisolone, and that the prednisolone metasulphobenzoate enema has a similar tolerability profile to a sucralfate enema (Table 2) . A few trials have been conducted to investigate the effects of prednisolone metasulphobenzoate on bone formation or bone mineral density. These found that short-term oral controlled-release prednisolone metasulphobenzoate had no effect on bone formation (measured by osteocalcin levels) or bone mineral density after 4 months of treatment in patients with active ulcerative colitis [Darlow et al. 2004 ]. However, conflicting results were reported in two studies that investigated the effects of short-course prednisolone metasulphobenzoate foam enemas (20 mg twice daily) on bone formation in patients with distal ulcerative colitis. One observational study showed that prednisolone metasulphobenzoate was associated with a significant reduction in bonespecific alkaline phosphatase activity [Robinson et al. 1997 ]. In contrast, another randomized, activecontrolled trial showed that neither prednisolone metasulphobenzoate nor hydrocortisone acetate enemas were associated with a reduction in serum osteocalcin or bone-specific alkaline phosphatase levels, suggesting no effect of treatment on bone turnover ]. Due to these conflicting results, no concrete conclusions regarding the effects of prednisolone metasulphobenzoate can be made. It is important for physicians to be aware of the potential bone-related effects associated with prednisolone metasulphobenzoate in patients with ulcerative colitis, and monitoring of such patients is therefore recommended.
Conclusion
Glucocorticosteroids are the most common therapy for the induction of remission in the active phases of IBD. Unfortunately, their use is burdened by important side effects. New formulations of glucocorticosteroids have been introduced with the intention of maintaining the efficacy of systemic steroids, while reducing the number of side effects, and in the case of the latter they have been successful. Nevertheless, compared with systemic administration, the improved tolerability profile of local steroids is accompanied by reduced efficacy.
Budesonide is the first glucocorticosteroid that has been extensively investigated for the treatment of Crohn's disease. It has been shown to be beneficial for the induction of remission in these patients, but is not recommended for the maintenance of remission in patients with Crohn's disease. This recommendation is not completely accepted in clinical practice, mainly in the North of Europe, because many patients are treated for periods of over 1 year. Few studies have investigated the efficacy of budesonide in ulcerative colitis and the results of these are conflicting. Further research is warranted to establish the efficacy of budesonide in patients with ulcerative colitis. Furthermore, new formulations of budesonide which release the drug in the colon have been effective therapy for patients with active ulcerative colitis in initial studies. These findings merit more extensive study.
BDP has good efficacy and is an established treatment for patients with ulcerative colitis, but data are not extensive in patients with Crohn's disease. While glucocorticosteroids are not recommended for the maintenance of remission in patients with IBD, a promising recent study suggested that BDP might maintain the remission induced by a short course of systemic glucocorticosteroids, reducing the number of side effects. Further investigation to confirm the efficacy of BDP in this indication is warranted.
The efficacy of fluticasone propionate and prednisolone metasulphobenzoate for the treatment of IBD is not well established in published clinical trials. While the tolerability profiles of these glucocorticosteroids are favourable, more research investigating their efficacy in these patients is required.
Finally, given that the most important advantage of the new glucocorticosteroids is their improved safety profile, we must mention that there are no studies assessing prolonged treatment (of over 1 year), and it is well known that steroid-related side effects are mainly associated with long-term therapy. It is possible, therefore, that long-term therapy with new glucocorticoid formulations could be associated with the appearance of important side effects, although it is likely that these will be less severe than those seen with traditional systemic steroids.
